test

The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.

The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.

The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.

The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The European Molecular Genetics Quality Network, a provider of proficiency testing services for clinical genetics and molecular pathology labs, and its UK partner have been developing a new assessment scheme for NGS labs.

The company launched a blood-based diagnostic to guide treatment strategies for lung cancer patients with ALK fusions who don't have sufficient tumor biopsy material for analysis by tissue-based tests.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.